Legal Affairs

Bioxyne Double-Strikes in LATAM and Europe

SYDNEY – Bioxyne Limited, an international health and life sciences company focused on the manufacturing and distribution of novel medicines, including medical Cannabis, psilocybin, and MDMA, has signed two new commercial agreements – one stretching ...

Rubicon Organics Reports Q1 2026 Financial Results

VANCOUVER – Rubicon Organics Inc. delivered its first-quarter report, revealing results that show both progress and short-term pressures common in an industry shifting toward larger-scale operations – all while balancing strong market share gains with ...

Cannara Biotech Reports Q2 2026 Financial Results

MONTREAL – Cannara Biotech Inc. posted its fiscal second-quarter results, recording higher revenues and a sharp improvement in cash generation as the Quebec-based producer continued to pick up ground in a flat national Cannabis market. ...

Bioxyne Double-Strikes in LATAM and Europe

SYDNEY – Bioxyne Limited, an international health and life sciences company focused on the manufacturing and distribution of novel medicines, including medical Cannabis, psilocybin, and MDMA, has signed two new commercial agreements – one stretching ...

Rubicon Organics Reports Q1 2026 Financial Results

VANCOUVER – Rubicon Organics Inc. delivered its first-quarter report, revealing results that show both progress and short-term pressures common in an industry shifting toward larger-scale operations – all while balancing strong market share gains with ...

Medical Cannabis: Growth and Investment in 2024

LOS ANGELES- The medical cannabis industry is navigating 2024 with key players like Grow Group and Somai Pharmaceuticals leveraging new regulations and market dynamics to achieve ambitious growth targets. This article examines the recent developments ...

Constellation Brands: Analysts Maintain Ratings

LOS ANGELES- On Monday, Argus reaffirmed its Buy rating on shares of Constellation Brands (NYSE: STZ), maintaining a price target of $306.00. Argus notes the stock's value, currently trading at 18 times the firm's fiscal ...

Critics Slam Thai Government’s Approach to Cannabis

LOS ANGELES- Critics have strongly opposed the Thai government's plan to reclassify cannabis as a narcotic, arguing that it will harm businesses involved in cannabis-based products and undermine investor confidence in the country. On July ...

Constellation Brands: Analysts Maintain Ratings

LOS ANGELES- On Monday, Argus reaffirmed its Buy rating on shares of Constellation Brands,  maintaining a price target of $306.00. Argus notes the stock's value, currently trading at 18 times the firm's fiscal year 2025 ...

Subscribe To Our Newsletter